AXIM (AXIM Biotechnologies) Operating Income: $-0.29 Mil (TTM As of Jun. 2025)


What is AXIM Biotechnologies Operating Income?

AXIM Biotechnologies AXIM -20.00% Operating Income is $-0.29 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

AXIM Biotechnologies's Operating Income for the three months ended in Jun. 2025 was $-0.02 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.29 Mil.

Warning Sign:

AXIM Biotechnologies Inc had lost money in 92% of the time over the past 12quarters.

Operating Margin % is calculated as Operating Income divided by its Revenue. AXIM Biotechnologies's Operating Income for the three months ended in Jun. 2025 was $-0.02 Mil. AXIM Biotechnologies's Revenue for the three months ended in Jun. 2025 was $0.00 Mil. Therefore, AXIM Biotechnologies's Operating Margin % for the quarter that ended in Jun. 2025 was %.

AXIM Biotechnologies's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AXIM Biotechnologies's annualized ROC % for the quarter that ended in Jun. 2025 was -1.13%. AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 684.94%.

AXIM Biotechnologies  (OTCPK:AXIM) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AXIM Biotechnologies's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-0.088 * ( 1 - 0% )/( (8.031 + 7.573)/ 2 )
=-0.088/7.802
=-1.13 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.346 - 1.984 - ( 0.007 - max(0, 6.677 - 0.008+0.007))
=8.031

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.224 - 1.854 - ( 0.003 - max(0, 6.206 - 0.003+0.003))
=7.573

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.524/( ( (0.227 + max(-6.599, 0)) + (0.218 + max(-6.104, 0)) )/ 2 )
=1.524/( ( 0.227 + 0.218 )/ 2 )
=1.524/0.2225
=684.94 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.001 + 0) - (1.984 + 0.499 + 4.117)
=-6.599

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.854 + 0.01 + 4.24)
=-6.104

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

AXIM Biotechnologies's Operating Margin % for the quarter that ended in Jun. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-0.022/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

AXIM Biotechnologies Operating Income Related Terms

AXIM Biotechnologies Operating Income Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Operating Income Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.83 -7.73 -4.65 -2.75 -1.76

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.57 0.00 -0.27 -0.02

AXIM Biotechnologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-0.29 Mil mean?
AXIM Biotechnologies (AXIM) has a Operating Income of $-0.29 Mil as of Jun. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Operating Income too high?
AXIM Biotechnologies' current Operating Income is $-0.29 Mil.
How does AXIM Biotechnologies' Operating Income compare to ZVSA and HEPA?
AXIM Biotechnologies' Operating Income of $-0.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Operating Income is $-0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Operating Income of $-0.29 Mil. The current Operating Income is $-0.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Operating Income is $-0.29 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.